Facebook Instagram Youtube
Speak to our experts

Stem Cell Therapy for Chronic Obstructive Pulmonary Disease (COPD)

At the Stem Cells Transplant Institute in Costa Rica, we offer stem cell therapy programs for COPD, including emphysema and chronic bronchitis, designed to support lung health, inflammatory regulation, and breathing comfort through regenerative medicine approaches. Current research suggests it may help support pulmonary tissue health and complement standard respiratory care.

Request a consultation
Learn our protocol
Reviewed: 11 May 2026

What is COPD?

Chronic obstructive pulmonary disease (COPD) is a group of chronic, progressive lung conditions characterized by airflow limitation and impaired gas exchange. It is driven by airway inflammation, structural airway changes, and damage to the alveoli (the tiny air sacs responsible for oxygen absorption).

Globally, COPD is a major cause of illness and death. The World Health Organization (WHO) estimates that hundreds of millions of people live with COPD, and millions die from COPD each year.

request a free consultation

Why Seek Stem Cell Therapy for COPD in Costa Rica?

Stem Cells Transplant Institute provides MSC-based respiratory protocols for COPD patients in San José, Costa Rica, within a certified medical facility. The institute offers regenerative medicine programs designed to complement conventional pulmonary care. Treatment protocols utilize laboratory-processed mesenchymal stem cells and are administered within controlled clinical environments under medical oversight.

Because respiratory function is an important consideration when planning travel, all COPD patients undergo a detailed medical screening and pulmonary review before therapy is scheduled. This evaluation helps determine whether travel is appropriate. San José is under six hours from major North American cities. Patients also choose Costa Rica because it is significantly more affordable than equivalent private options in the United States or Canada.

Spirometry data, exacerbation history, current medications, and oxygen requirements are part of every pre-treatment review. If the clinical picture suggests the visit needs to be adjusted — in timing, duration, or protocol design — that conversation happens before travel is ever scheduled.

Common characteristics

  • Shortness of breath (especially with activity)
  • Chronic cough
  • Excess mucus (sputum) production
  • Wheezing or chest tightness
  • Reduced exercise tolerance and fatigue
  • Swelling in the lower extremities in more advanced disease
Evidence-Based Treatment

Why Stem Cell Therapy for COPD?

Chronic Obstructive Pulmonary Disease (COPD) is a long-term lung condition that most often includes chronic bronchitis and emphysema. In chronic bronchitis, the airways become irritated and inflamed. This can cause excess mucus, narrowing of the breathing tubes, and ongoing shortness of breath. In emphysema, the tiny air sacs in the lungs (alveoli) are damaged. This reduces the lungs’ ability to move oxygen into the bloodstream and can make it difficult to fully exhale air.

Researchers are exploring mesenchymal stem cells (MSCs) because these cells release natural signaling substances (paracrine factors) that may help influence inflammation and immune balance in the lungs. While early studies suggest potential biological effects, larger and well-controlled clinical trials are still needed to determine whether this approach leads to consistent, meaningful improvements beyond standard medical care.

Evidence remains preliminary, and ongoing controlled clinical trials are required to confirm the magnitude and consistency of these effects.

1

Supporting a healthier immune response

COPD involves ongoing inflammation in the airways. Rather than replacing damaged lung tissue directly, MSCs mainly work by releasing signaling molecules (secreted factors and extracellular vesicles) that may help calm excessive inflammation and encourage a more balanced immune response.(Chen et al., 2021)

2

Helping protect lung cells from oxidative and inflammatory injury

Long-term inflammation and oxidative stress can continue to injure lung tissue in COPD. Early research suggests that substances released by MSCs may help lung cells better tolerate this stress and reduce the activity of inflammatory chemicals involved in tissue damage.(Chen et al., 2021)

3

Supporting natural repair processes in the lungs

In laboratory and early clinical studies, MSCs have been shown to release growth and regulatory factors that may help create a more supportive environment for lung tissue, potentially aiding the body’s own repair signaling over time. (Chen et al., 2021)

4

Supporting blood vessels and the lung environment

COPD can also affect the small blood vessels in the lungs, which play an important role in oxygen exchange. Some regenerative medicine studies suggest MSCs may help support the health of these blood vessels and the surrounding lung environment, although this area is still being actively researched.(Chen et al., 2021)

request a free consultation

Expected Benefits & Clinical Observations

Although individual responses vary widely, published studies and clinical observations have reported potential supportive improvement in the following functional domains:

Reduction in inflammatory markers
20-40%
Improvement in exercise tolerance
25-50%
Reduced severity of flare-ups
25-40%
Improved quality of life
30-45%

*These percentages summarizes ranges reported in selected clinical studies and observational cohorts under controlled conditions and standardized outcomes measures. They are not specific to any single study or to treatments performed at Stem Cells Transplant Institute. They should not be interpreted as averages, promises, or guaranteed results for individual patients. Evidence for MSC therapy in COPD disease remains preliminary, and ongoing controlled clinical trials are still evaluating the magnitude, durability and consistency of these effects. All observations should be considered exploratory and hypothesis-generating rather than definitive proof of efficacy.

 Timeline of Reported Improvements

Published studies and patient-reported outcomes suggest that improvements after mesenchymal stem cell (MSC) therapy for COPD may develop gradually over time. These timelines are illustrative summaries rather than predictions, and individual responses vary significantly.

1-3 months
Some individuals report easier breathing and reduced morning congestion.
3-6 months
Some individuals report improvements in lung function and exercise capacity
6-12 months
Some individuals report sustained anti-inflammatory effects and stability

*These timelines summarize patterns reported across selected published studies and observational cohorts. They are not specific predictions, and they do not represent expected outcomes for any individual patient. Individual experiences vary considerably, and some patients may experience minimal or no improvement. Evidence for MSC therapy in COPD remains preliminary, and larger controlled clinical trials are needed to validate these observations. All timelines should be interpreted as exploratory and non-confirmatory.

request a free consultation

Patient Stories & Testimonials

Frequently Asked Questions

Costs vary depending on the number of stem cell infusions and the specific treatment plan recommended after your medical review. We can provide pricing only after evaluating your case to ensure the therapy is appropriate and safe. Any pricing or estimate provided is informational and non-binding, may change after clinical assessment, and does not include travel or accommodation unless explicitly stated.

You can begin by sending your medical history, imaging, and recent pulmonary function tests to us for evaluation. If you are deemed a suitable candidate, the team will help you schedule treatment dates, provide information on transportation options, and guide you through travel logistics. Many patients complete their entire pre-arrival assessment remotely. Final eligibility and the treatment plan are confirmed only after a clinical review, and scheduling is subject to availability

No. COPD is a chronic, progressive condition that cannot be cured. However, stem cell therapy is being studied for its potential to reduce inflammation and support respiratory function in some patients. Evidence is still evolving, results vary, and no outcome can be guaranteed.

Some patients report noticing changes within 1–3 months, with continued follow-up over 6–12 months. However, timing and degree of any change vary significantly by individual and disease severity, and improvements are not guaranteed.

We use mesenchymal stem cells (MSCs)—typically sourced from either your own tissue or donated umbilical cord tissue. depending on your medical assessment and treatment plan. All cells are obtained from legally authorized sources with appropriate donor screening and quality controls. MSCs are favored because of their anti-inflammatory and lung-protective properties.

As with any medical procedure, risks exist. Reported side effects from MSC therapy are often described as mild and temporary (such as fatigue or soreness), but individual reactions vary. Serious complications are rare but possible. Long-term risks are still being studied, and no outcome can be guaranteed. A medical team will evaluate your health profile to determine if treatment is appropriate and to review monitoring and follow-up recommendations.

No. Stem cell therapy is considered complementary and is typically done in addition to, not in place of, prescribed medications and pulmonary rehabilitation. Do not stop or change any inhalers or COPD medications unless instructed by your treating physician/pulmonologist.

Many patients travel safely with COPD but may need special considerations such as arranging oxygen, choosing an appropriate flight length, or traveling with medication documentation. The clinic can help coordinate travel needs if required. However, travel safety depends on disease severity and your overall health status, and your treating physician/pulmonologist should advise you on fitness to fly and any in-flight oxygen requirements.

contact an expert today

Key Research Studies

Stem Cell Therapy for Chronic Obstructive Pulmonary Disease

Chinese Medical Journal • 2021

Scientific review evaluating clinical evidence and therapeutic mechanisms of stem cell therapy as a potential regenerative treatment approach for COPD.

View published study

Mesenchymal Stem Extracellular Vesicles in Respiratory Diseases

Journal of Inflammation Research • 2024

Research review analyzing how MSC-derived extracellular vesicles may support repair processes and immune modulation in respiratory disorders.

View published study

Placebo-Controlled Trial of Mesenchymal Stem Cells in COPD Patients

Chest • 2013

Controlled clinical trial evaluating safety and therapeutic outcomes of mesenchymal stem cell treatment in individuals diagnosed with COPD.

View published study

Stem Cell Therapies for COPD: Mesenchymal Stem Cells as a Promising Treatment

Stem Cell Research & Therapy • 2024

Scientific review highlighting regenerative mechanisms and clinical potential of mesenchymal stem cell therapy for chronic obstructive pulmonary disease.

View published study
info
Location

San José, Costa Rica

Contact Us

info@stemcellstransplantinstitute.com

Call Center

+1 888 785-4170

APPLY TODAY